On September 27th, HTDK was recognized on the 2022 “CHUANG・Qi Hang” Global Emerging Tech Innovators list, following unanimous selection by the Sullivan-Toubao Sci-Tech Expert Committee. HTDK, with its mission to enhance the accessibility of innovative global medical devices in China, has been honored for its leadership in the high-value medical device sector.

This year, Sullivan, in collaboration with Toubao Research Institute, launched the “CHUANG・Qi Hang” Global Emerging Tech Innovators 2022 evaluation. The selection aims to identify companies with strong future growth potential, sustainable development capabilities, and both national and international expansion opportunities. These companies demonstrate a clear competitive edge and are poised to become industry leaders. After more than two months of evaluation, the expert committee unveiled the final list, which includes 36 international companies and 44 domestic companies. The companies span multiple sectors, including biomedicine, consumer retail, internet and technology, entertainment and media, financial services and fintech, energy and power, mechanical manufacturing, and industrial materials.

The committee commended HTDK, stating: “As a leading private commercial solutions platform in China’s high-value medical device sector, HTDK is committed to improving the accessibility of innovative global medical devices in China. Through its specialized, customized, and comprehensive one-stop commercial solutions, the company has become a top partner for global medical brands entering and expanding in the Chinese market. HTDK has consistently provided world-class services to China’s rapidly growing market, leveraging a global perspective to support partner brands’ entry and penetration into China, earning a high standard, high-value international benchmark status within the industry.”

The selection of HTDK on the “CHUANG・Qi Hang” list reaffirms its leadership in the biomedicine sector, showcasing its continued commitment to driving innovation and collaboration between global medical brands and the Chinese market.